Permixon®, hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells

Tamalunas, Alexander; Wendt, Amin; Springer, Florian; Vigodski, Victor; Ciotkowska, Anna; Rutz, Beata; Wang, Ruixiao; Huang, Ru; Liu, Yuhan; Schulz, Heiko; Ledderose, Stephan; Kolben, Thomas; Magistro, Giuseppe; Stief, Christian G.; Hennenberg, Martin

doi:10.1016/j.lfs.2022.120931

Cited by 8 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data show that by reducing the underlying persistent PIS, HESr provides additional LUTS/BPH symptom relief when combined with α-blockers, including improvements in the voiding and storage IPSS and urinary flow rate. Furthermore, a recent publication has shown that HESr may inhibit neurogenic, α1-adrenergic and thromboxane-induced smooth muscle contraction in the prostate tissue as well as methacholine-induced contractions of the bladder detrusor smooth muscle in vitro [ 48 ]. Additionally, HESr treatment inhibited prostate stromal cell growth and actin formation [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, a recent publication has shown that HESr may inhibit neurogenic, α1-adrenergic and thromboxane-induced smooth muscle contraction in the prostate tissue as well as methacholine-induced contractions of the bladder detrusor smooth muscle in vitro [ 48 ]. Additionally, HESr treatment inhibited prostate stromal cell growth and actin formation [ 48 ]. These results provide evidence that can explain the ubiquitously beneficial effects of HESr reported by patients and seen in clinical trials and give rationale for HESr combination approach with α-blockers ( Figure 5 ).…”

Section: Discussionmentioning

confidence: 99%

“…HESr inhibitory effects (green) on different targets and shared intracellular mediators contribute to the LUTS/BPH symptom relief on multiple levels. Modified from [ 47 , 48 ]. TXA2-R—tromboxane A2 receptor; α1A-AR—α1A-adrenoreceptor.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH

Nunzio

Salonia

Gacci

et al. 2022

JCM

View full text Add to dashboard Cite

The hexanic extract of Serenoa repens (HESr) has been in use for decades as an effective, safe and well-tolerated therapy for relieving bothersome lower urinary tract symptoms (LUTS) associated with benign prostate hyperplasia (BPH). This manuscript gives an overview of HESr as monotherapy for LUTS/BPH treatment and focuses on the currently available literature investigating the possible clinical benefits of HESr combination therapy with α-blockers. Combination therapy of HESr with α-blockers has been gaining significant interest in recent years, as an increasing body of evidence shows the beneficial pharmacological effects that HESr treatment can add to standard first-line treatment with α-blockers. By reducing persistent Prostatic Inflammatory Status (PIS), commonly present in LUTS/BPH patients, HESr complements the relaxation of prostate smooth muscle induced by α-blockers, thus providing additional symptom relief. Data suggest that patients harbouring PIS and having a specific clinical profile might especially benefit from the combination therapy. Future therapeutic efforts may take advantage of more personalised strategies for LUTS/BPH management.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH

Nunzio

Salonia

Gacci

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…AUA guidelines do not currently recommend any supplements or herbal preparations. Permixon ® has been shown to inhibit smooth muscle contraction in both the prostate and detrusor as well as inhibiting prostate stromal cell growth [43].…”

Section: Supplementsmentioning

confidence: 99%

Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques

Hughes,

Harper,

Somani

2023

Life

View full text Add to dashboard Cite

The management of benign prostatic obstruction (BPO) should involve a treatment algorithm that takes into account prostate size, and patient’s symptoms and preference with the aim of helping with urinary symptoms and enhance quality of life. The diagnostic assessment for men with lower urinary tract symptoms (LUTS) should be comprehensive to help choose the best management strategy. Strategies from lifestyle modifications to medical treatment with alpha blockers and/or 5-alpha-reductase inhibitors to surgical procedures can all be used in the management algorithm. Surgical management ranges from transurethral resection of prostate (TURP) to minimally invasive surgical therapies (MIST) including laser therapies such as Holmium laser enucleation (HoLEP) and photoselective vaporisation (PVP), aquablation, Rezūm system, prostate artery embolisation (PAE), prostatic urethral lift (PUL), temporary implantable nitinol device (iTind) and Optilume BPH catheter system. BPO is a common urological condition that has a significant impact on quality of life and economic burden globally and is likely to become increasingly prevalent with an ageing population. Selecting the most appropriate treatment modality will depend on the individual patient preferences, availability of resources, cost, anatomical factors and the goals of treatment.

show abstract

“…продемонстрировали ингибирующее действие HSRE на сокращение гладких мышц предстательной железы и мочевого пузыря человека. Применение HSRE вызывало дозозависимое ингибирование сокращения гладкомышечных элементов предстательной железы, вызванное адренергической стимуляций, на 30-60%, что подтвердило неконкурентное связывание компонентов экстракта с α1-адренорецепторами [120,121]. Это дополнило и дало новое объяснение ранее выявленному благоприятному эффекту SRE, полученных разными методами экстракции, в отношении широкого спектра агонистов сокращения в богатых гладкими мышцами органах, в том числе в нижних мочевыводящих путях, что указывает на неконкурентное связывание с α1-адренорецепторами как на классовый эффект SRE, при том, что активность и эффективность экстрактов различались [110,112].…”

Section: регулирующее действие Hsre на нейрогенные структуры мочевого...unclassified

Hypothesis about the possible mechanisms of therapeutic action of Serenoa repens hexane extract on the hypertrophied bladder in accordance with the pathogenesis of its dysfunction caused by bladder outlet obstruction.

Сивков¹,

Kirpatovskiy²

2023

ECU

View full text Add to dashboard Cite

Introduction. Traditionally it is believed that the therapeutic effect of the hexane extract of Serenoa repens (HSRE) in patients with benign prostatic hyperplasia is realized due to its effect on prostate cells. However, in the literature there is data about the possible HSRE effect not only on the prostate, but also directly on the bladder. This paper summarizes data and analyzes the possible cellular mechanisms of HSRE action on the bladder under the development of infravesical obstruction (bladder outlet obstruction – BOO). Materials and methods. Literature data from the PubMed and eLibrary.ru databases for a 25-years period related to the study of the pathogenesis of bladder dysfunction in the development of BOO, cellular and molecular mechanisms by which pathological and adaptive processes in bladder cells are realized, as well as the influence of HSRE on these processes are analyzed. Results. The concept of the pleiotropic effect of HSRE on various links in the pathogenesis of bladder dysfunction caused by BOO has been formed. The main of which are: the antioxidant and anti-inflammatory effects of HSRE components, as well as the regulatory effect on cell growth and proliferation factors and transcription factors. All this reduces the cytotoxic effect of oxidative stress on the cells of the bladder developing in IVO, contributing to a more active proliferation of detrusor smooth muscle cells. The consequence of the complex action is to maintain the contractile function of the bladder in a state of adaptation to increased stress, due to BOO. Conclusions. The present hypothesis about the direct effect of HSRE on the hypertrophied bladder and possible mechanisms of its therapeutic action is based on an understanding of the general biological mechanisms and allows us to explain better the results of previous clinical studies and to assess the prospects for expanding the scope of further drug application.

show abstract

Permixon®, hexane-extracted Serenoa repens, inhibits human prostate and bladder smooth muscle contraction and exerts growth-related functions in human prostate stromal cells

Cited by 8 publications

References 52 publications

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH

Treatment Algorithm for Management of Benign Prostatic Obstruction: An Overview of Current Techniques

Hypothesis about the possible mechanisms of therapeutic action of Serenoa repens hexane extract on the hypertrophied bladder in accordance with the pathogenesis of its dysfunction caused by bladder outlet obstruction.

Contact Info

Product

Resources

About